Ocular Therapeutix Inc. Announces Participation in Key Scientific Conferences
On October 7, 2025, Ocular Therapeutix Inc. (NASDAQ: OCUL), a pioneering biopharmaceutical company focused on redefining the retina experience, unveiled its plans to participate in several prominent scientific conferences this month. These events will serve as platforms for the company to showcase its innovative research and developments in the field of ophthalmology.
1. Upcoming Conference Schedule
American Academy of Optometry
Dates: October 8 - 11, 2025
Location: Boston, Massachusetts
Ocular Therapeutix's participation kicks off at the American Academy of Optometry. The company will present a poster titled "Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial." This presentation is scheduled for October 9, 2025, from 4:30 – 6:30 PM ET, featuring insights from Trung Tran, OD, Senior Medical Director at Ocular Therapeutix.
Eyecelerator @ AAO 2025
Date: October 16, 2025
Location: Orlando, Florida
Next, Ocular Therapeutix will take part in the Eyecelerator showcase at the American Academy of Optometry meeting. During this session, the company will present "Ocular Therapeutix: Redefining the Retina Experience," providing an overview of its strategic vision and the advancements in its product pipeline. This presentation will be delivered by Peter K. Kaiser, MD, Chief Development Officer, on October 16, 2025, from 1:15 – 2:45 PM ET.
American Academy of Ophthalmology
Dates: October 18 - 20, 2025
Location: Orlando, Florida
Ocular Therapeutix will also feature in the American Academy of Ophthalmology's annual meeting with an on-demand poster titled "Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy." This presentation can be viewed throughout the congress, catering to attendees interested in the latest findings from Margaret Chang, MD, MS.
2. Focus on Innovative Treatments
Ocular Therapeutix is at the forefront of developing novel therapies for retinal diseases. Its investigational product candidate, AXPAXLI™ (OTX-TKI), represents a significant advancement in the treatment of retinal conditions. This axitinib intravitreal hydrogel is based on Ocular's proprietary ELUTYX™ technology and is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). Additionally, the company is gearing up to initiate a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) imminently.
The company has made waves in the sector with its commercial product, DEXTENZA®, an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, as well as ocular itching associated with allergic conjunctivitis in both adult and pediatric populations.
3. Conclusion
Ocular Therapeutix's active participation in these key conferences highlights its commitment to innovation and leadership in ophthalmic care. As the company continues to advance its pipeline and engage with the scientific community, stakeholders and investors will be keenly watching for updates on its progress and the outcomes of its ongoing clinical trials. With a robust lineup of presentations, Ocular Therapeutix is poised to make a significant impact at these events and beyond.
